Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LibidUp-PE is a nutraceutical supplement developed by MMC Pharmaceuticals (marketed under their Ziva division) specifically for the management of premature ejaculation (PE) and male sexual dysfunction. Formulated as a 10g sachet, it contains a combination of essential amino acids, vitamins, and herbal extracts, including L-arginine, L-tryptophan, myo-inositol, D-chiro-inositol, vitamin B6, grape seed extract, and Safed Musli. The product is designed to enhance sexual wellness, boost stamina and vigor, and regulate the ejaculatory cycle. Clinical data from a 2023 randomized, double-blind crossover study demonstrated that LibidUp-PE significantly improves intravaginal ejaculatory latency time (IELT) and reduces post-ejaculatory refractory time (PERT). Its mechanism of action involves increasing plasma serotonin levels, which helps delay ejaculation, and enhancing blood flow to address concerns like erectile dysfunction. It is currently marketed in India.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LibidUp-PE.